A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients
- Conditions
- Herpes SimplexHIV Infections
- Registration Number
- NCT00002000
- Lead Sponsor
- Glaxo Wellcome
- Brief Summary
To evaluate the safety and efficacy of oral valacyclovir hydrochloride (256U87) vs. acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients (CD4 greater than or equal to 100).
- Detailed Description
Efficacy variables include the length of the episode, the time to lesion healing, the duration and severity of pain/discomfort, the duration of viral shedding, the proportion of patients with aborted episodes, the proportion of patients requiring extended therapy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (22)
Univ of South Alabama
🇺🇸Mobile, Alabama, United States
ViRx Inc
🇺🇸San Francisco, California, United States
UCSF - San Francisco Gen Hosp
🇺🇸San Francisco, California, United States
Denver Public Health Dept / Disease Control Services
🇺🇸Denver, Colorado, United States
West Haven Veterans Administration Med Ctr
🇺🇸West Haven, Connecticut, United States
Univ of South Florida
🇺🇸Tampa, Florida, United States
Emory Univ School of Medicine
🇺🇸Atlanta, Georgia, United States
Northwestern Memorial Hosp
🇺🇸Chicago, Illinois, United States
Rush Presbyterian - Saint Luke's Med Ctr
🇺🇸Chicago, Illinois, United States
Infectious Diseases Research Clinic / Indiana Univ Hosp
🇺🇸Indianapolis, Indiana, United States
Scroll for more (12 remaining)Univ of South Alabama🇺🇸Mobile, Alabama, United States